Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using quantitative ultrasound, texture, and molecular features

Abstract

BackgroundPathological response of breast cancer to chemotherapy is a prognostic indicator for long-term disease free and overall survival. Responses of locally advanced breast cancer in the neoadjuvant chemotherapy (NAC) settings are often variable, and the prediction of response is imperfect. The purpose of this study was to detect primary tumor responses early after the start of neoadjuvant chemotherapy using quantitative ultrasound (QUS), textural analysis and molecular features in patients with locally advanced breast cancer.MethodsThe study included ninety six patients treated with neoadjuvant chemotherapy. Breast tumors were scanned with a clinical ultrasound system prior to chemotherapy treatment, during the first, fourth and eighth week of treatment, and prior to surgery. Quantitative ultrasound parameters and scatterer-based features were calculated from ultrasound radio frequency (RF) data within tumor regions of interest. Additionally, texture features were extracted from QUS parametric maps. Prior to therapy, all patients underwent a core needle biopsy and histological subtypes and biomarker ER, PR, and HER2 status were determined. Patients were classified into three treatment response groups based on combination of clinical and pathological analyses: complete responders (CR), partial responders (PR), and non-responders (NR). Response classifications from QUS parameters, receptors status and pathological were compared. Discriminant analysis was performed on extracted parameters using a support vector machine classifier to categorize subjects into CR, PR, and NR groups at all scan times.ResultsOf the 96 patients, the number of CR, PR and NR patients were 21, 52, and 23, respectively. The best prediction of treatment response was achieved with the combination mean QUS values, texture and molecular features with accuracies of 78%, 86% and 83% at weeks 1, 4, and 8, after treatment respectively. Mean QUS parameters or clinical receptors status alone predicted the three response groups with accuracies less than 60% at all scan time points. Recurrence free survival (RFS) of response groups determined based on combined features followed similar trend as determined based on clinical and pathology.ConclusionsThis work demonstrates the potential of using QUS, texture and molecular features for predicting the response of primary breast tumors to chemotherapy early, and guiding the treatment planning of refractory patients.

Breast Cancer Assessment With Pulse-Echo Speed of Sound Ultrasound From Intrinsic Tissue Reflections

“…This could potentially reduce the number of false-positive biopsies as well as the number of falsely down-staged lesions. Similarly to what has already been shown for US by Sannachi et al 50 and for SoS US by Lupinacci et al, 51 SoS-US could potentially be used as a fast and easy tool to predict the tumor response to chemotherapy. The current resolution is too low to make a conclusive statement on inner lesion structure.…”

Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status

“…In recent years, most studies used GLCM texture features for predicting the molecular subtypes of breast tumors or the pathological response to neoadjuvant chemotherapy (49,50). In this study, additional features were explored, such as histogram features, GRLM features, and DWT features, and the experimental results of univariate analysis demonstrated that those features were highly related to HER2 2+ expression status.…”

Germline variant burden in multidrug resistance transporters is a therapy‐specific predictor of survival in breast cancer patients

“…Our results demonstrate that BRCA patients with high variant burden in ABCC1 are less prone to respond appropriately to pharmacological therapy with MRP1 substrates. Thus, such at-risk individuals are likely to benefit from earlier and more frequent monitoring, ideally using more sensitive methods, such as magnetic resonance imaging 58 or quantitative ultrasound spectroscopy, 59,60 which can detect early events (tumor cell death) that precede changes in tumor size.…”